I agree that misiu and yourself are likely correct
I agree that misiu and yourself are likely correct (especially since this is a rare topic that Fine also agreed with both of you....or maybe she was trying to sell when we discussed this?).
Where I was getting hung up is the insurance paying for it, but maybe they do not look at deep enough to see if the patient is resistant at all and only see HIV patient (R2+ patient coded differently than R1 patients)? That could very well be or even if they do code differently based on the R class, maybe their is no risk to the Dr.'s prescribing off-label as insurance companies do not seek legal action or try to recoup money for off-label use.....if this is true, then the only risk for Dr. prescribing off-label would be malpractice concerns....but this seems unlikely because as you both noted the safety profile of leronlimab and how Dr.'s and patients are waiting for such a drug for easier compliance and patient safety. Your explanation helped me see this more clearly and likely what misiu explained to me previously and I just didn't grasp (sorry misiu for the unnecessary frustration......I can be like talking to a rock sometimes : ).
This would be a welcomed event once sales begin. I likely will not changed my expectations as the company last stated they only expect >$480M revenues in 2020 and if they update these figures, they may even reduce this if combo approval is delayed very much. What I'm not sure is whether these revenue estimates are based on a % of sales due to a license agreement or overall revenue and a very small market penetration which at $70,000/annual per patient is only 6,858 patients (13,716 patients if only 6 months 2020 sales at $35,000). I think your expectations is that they can easily exceed these estimates, which I concur, but for planning purposes I will keep my expectations low and hopefully be pleasantly surprised.
Thank you for enlightening me once again!
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Digging into HERVolution's Game-Changing Data Picture HERVolution in the spotlight, rolling out data that could shake up our approach to cancer immunotherapy. The big headline? HERV-K antigens might just be the whistle-blower we've been looking for to get the immune system off the bench and onto the field. How's that for a kick in the conventional wisdom of cancer...
Continue Reading
A Month of Patriotism and Service You've got to hand it to the Daughters of the American Revolution (DAR)—when they commit, they go all in. This year, they turned their usual Day of Service into a full-blown Month of Service, packing in over 587,000 hours of volunteering nationwide. From historic spots to food pantries, DAR members showed up, and honestly, it's the kind...
Continue Reading
Landis+Gyr's Multi-Faceted Financial Leap In the unpredictable landscape of energy tech, Landis+Gyr has thrown down some noteworthy cards in their latest financial disclosures. We're talking a Q2 net revenue sitting pretty at $269.2 million, and it's no mistake they landed a record-smashing adjusted gross margin of 38.0%. All this while wrangling an order intake of $170.3...
Continue Reading
A Timepiece That Redefines Everyday Elegance There's a new player in the vast realm of watches, and it's got tongues wagging: the Casio CMK?100. You don’t see that blend of style, comfort, and practicality grow on trees, my friend. Casio’s new offering, the CMK?100, wears its purpose on its titanium sleeve: lightweight and stylish, it’s a suave addition to any wrist...
Continue Reading
Yale’s Inflammation Research: Beyond the Basics Inflammation. It’s the kind of battle your own body wages from within, and Yale School of Medicine’s fresh $10 million grant from the Blavatnik Family Foundation means they’re marching deeper into the trenches. This is not another academic exercise; it’s about digging out the roots of diseases that are tough to pin...
Continue Reading
A New Era for MPLX's Board Nothing shakes up the scene like announcing two heavyweights joining the board, and that's exactly what MPLX LP (NYSE: MPLX) just pulled off. Micheal G. Dunn and Bruce L. Niemeyer are coming onboard, effective November 1, 2026. With pedigrees that could make any industry insider nod in approval, these guys bring decades of experience to the...
Continue Reading
7-Eleven's New Global Menu Twist October 2026 sees 7-Eleven, Inc. whip out an intriguing move, venturing east with its new Flavors of Korea menu. They're not just changing the game in convenience store aisles; they're dancing to the beat of global flavors—a shake-up fit for the world's largest convenience retailer. Think about bodega basics getting a spicy Korean...
Continue Reading
Innovating the Turkey Call Game You want innovation? Well, wrap your head around this: a Missouri inventor is flipping the script on turkey mouth calls. The goal? To ditch the wrinkles and make turkey hunting that much smoother. It might seem a bit niche, but when you've been around long enough, you know these 'niche' ideas can sometimes hatch golden eggs for investors....
Continue Reading
Wyoming's Bid for Skilled Trades Revolution You’d think with all the talk about tech and white-collar jobs, we’ve forgotten the backbone that keeps the world ticking—skilled trades. Turns out, Bechtel hasn’t. The company just tossed a cool million at Wyoming's Laramie County Community College and Western Wyoming College. What’s that doing? It's jumpstarting...
Continue Reading
In the ever-evolving dance of political discourse, a new book strides onto the stage: Not My President, published by Palmetto Publishing. It’s a bold compilation of presidential utterances, capturing the words of Donald J. Trump in all their unvarnished glory. Stripped of analysis or comedic flair, each entry stands alone like a solitary figure at a cocktail party,...
Continue Reading
Top 5 Most Recently Viewed Articles
Empowering Future Medical Leaders The Dr. Konstantinos Zarkadas Scholarship for Future Doctors is now open for applications. This scholarship invites undergraduate students committed to the field of medicine to apply for a prestigious award. The scholarship, which amounts to a one-time award of $1,000, aims to assist a deserving student who exemplifies both academic...
Continue Reading
Pharma Two B and Hepion Pharmaceuticals Announce Merger KIRYAT ONO, ISRAEL and EDISON, N.J. — Pharma Two B Ltd., a leading late-stage pharmaceutical company focused on treating Parkinson’s Disease, has officially announced its merger with Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA), which specializes in addressing chronic liver diseases. They have filed a registration...
Continue Reading
Applied Graphite Technologies' Recent Developments Applied Graphite Technologies Corporation (AGT) has made significant strides in its operations recently by granting 2,350,000 stock options to its consultants, directors, and officers. These options are set at an exercise price of $0.07, and they come with a five-year term, expiring on August 13, 2030. This move...
Continue Reading
Jefferson's Big Move: A Strategic Overhaul The winds of change are blowing over at Jefferson Solutions Group. This May, the company announced a heavy-duty strategic reorganization to better align with its astronomical ambitions for long-term growth. If you're the type that's got a soft spot for high-impact solutions and government gigs, pay attention, because this shift...
Continue Reading
Unbeatable Security Solutions for Your Home This Summer As summer vacation approaches, ensuring the safety of your home becomes vital. Reolink, known for its innovative solutions in visual technology, has announced early Prime Day deals that will make securing your property both convenient and affordable. With these impressive offers, you can invest in top-rated security...
Continue Reading